Infant Discomfort

2

Review clinical trials related to Infant Discomfort. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Effects of Goat Milk Formula on Gastrointestinal Comfort and Growth in Infants

Infant gastrointestinal discomfort is common in early life and can affect feeding, sleep, and overall well-being. Goat milk formula, due to its unique protein composition and smaller fat globules, may be easier to digest and potentially improve gastrointestinal tolerance in infants. This study is a multicenter, randomized, controlled trial designed to evaluate the effects of goat milk formula compared with standard cow milk formula in infants aged 0-5 months with gastrointestinal discomfort. The study will assess improvements in gastrointestinal symptoms, overall comfort, behavioral status, and early growth and development, as well as explore potential changes in gut microbiota and intestinal inflammation.

Participants needed: 150
Trial details
Age: Up to 5Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Aug 21, 2026
Eligibility criteria

Infants aged 0 to 5 months at enrollment [+4]

Infants with known or suspected organic gastrointestinal diseases (e.g., congeni... [+5]

Status: Not yet recruiting

Dexmedetomidine for Invasive Ventilation In the NEOnate

Despite the increasing use of non-invasive ventilation, a large majority of premature neonates still receive invasive ventilation during their NICU (neonatal intensive care unit) stay. Invasive ventilation is a unanimous source of discomfort and pain. As opposed to the adult and pediatric population, routine use of opioids or midazolam is not recommended in ventilated neonates. Although opioids are the most frequently prescribed analgosedative drugs in ventilated premature neonates, their use is controversial because of the risk of respiratory depression - which can prolong invasive ventilation- and concerns on long-term neurodevelopment. Dexmedetomidine, a selective alpha-2- adrenergic agonist routinely used in the adult ICU (intensive care unit), provides light sedation and some analgesia with no or little respiratory-depression effect. It also has neuroprotective properties after pediatric cardiac surgery and in neonatal animal models. Dexmedetomidine is thus a promising candidate drug in ventilated premature neonates that might reduce the duration of mechanical ventilation and preserve neurodevelopment in this vulnerable population. The investigators hypothesize that the use of dexmedetomidine in ventilated premature neonates could decrease the need for opioids, facilitate extubation and thereby preserve long-term neurodevelopmental outcome.

Participants needed: 246
Trial details
Phase: Phase 2, Phase 3Age: Up to 10Biological sex: AllType: InterventionalSponsor: Centre Hospitalier Intercommunal CreteilUpdated: Mar 25, 2026Locations: 12
Eligibility criteria

Neonates with a gestational age at birth < 32 weeks of gestation and corrected g... [+4]

Previous inclusion in this trial [+9]